Peanut and Tree Nut AllergyALLERGYNCT05671471
Accidental Reactions in Peanut/Tree Nut Allergic Children
An observational study of Peanut and Tree Nut Allergy, run by University Hospital, Lille at 1 site in France.
Trial summary
Food allergy is an immune reaction, triggered by food protein allergens, of varying severity, from mild local reaction to life threatening anaphylaxis and fatalities. Peanut is a plant from the botanical family of the Fabaceae, more commonly known as legumes. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Peanut and Tree Nut Allergy
- How many people
- 147 participants
- Where
- 1 siteFrance
- Study dates
- 22 Sep 2021to 10 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients followed in the Pediatric Allergy and Pulmonology Unit, CHU Lille, aged 0-18 years with peanut and/or tree nut allergy
Who may be able to join
- Confirmed allergy to peanuts and/or nuts
Who cannot join
- Other chronic diseases, except allergic comorbidities (asthma, rhinitis, atopic dermatitis, other food allergy)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Accidental Reactions in a French Cohort of Children With Peanut and/or Tree Nut Allergy.
Food allergy is an immune reaction, triggered by food protein allergens, of varying severity, from mild local reaction to life threatening anaphylaxis and fatalities.
Peanut is a plant from the botanical family of the Fabaceae, more commonly known as legumes. The prevalence of peanut and tree nut allergy is increasing. In France (ELFE cohort), it is estimated to 0.93%. The tree nuts include mainly almond, hazelnut, pistachio, cashew nut, walnut, pecan nut and Brazil nut. Allergy's prevalence is estimated to 0.54% in children up to 5.5 years. Peanut allergy is a main cause of anaphylaxis and deaths due to food allergy.
Read more
Recurrence of food allergy is a main concern. The risk has been estimated to 10% per year for peanut.
In France, Data in real-life on the rate of recurrence of allergic reactions and anaphylaxis to peanut/tree-nut as well as risk factors, are lacking.
The objective of this study is to assess the frequency of allergic reaction to peanut and tree-nuts, to describe the reactions' characteristics and risk factors.
- Conditions
- Peanut and Tree Nut Allergy
- Keywords
- Peanut allergy, tree nut allergy, peanut immunotherapy, anaphylaxis, real life
- Medical subject headings
- Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, Nut Hypersensitivity, Anaphylaxis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Allergic Children | Patients followed in the Pediatric Allergy and Pulmonology Unit, CHU Lille, aged 0-18 years with peanut and/or tree nut allergy |
What is being measured
The primary outcome is the main question the study is designed to answer.
the number of episode of allergic reactions in real life
Measured: At 1 year
Secondary outcomes (3)
the severity of the allergic reactions according to a validated scale (FASS scale)
Measured: At 1 year
interview for the characteristics of the allergic reactions
the characteristics of the reactions: symptoms, triggering food and quantity, location, emergency kit available, treatment administered, evolution (hospitalization or emergency room)
Measured: At 1 year
interview to defined the risks factor associated
risk factors for reaction:
- Other known allergies
- Asthma
- Atopic dermatitis
- Allergic rhinoconjunctivitis
- Patient characteristics: sex, age
Measured: At 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2023
- Study start22 Sep 2021
- Primary completion10 Oct 2022
- Study completion10 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peanut and Tree Nut AllergyStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 147 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Antoine DESCHILDRE, MD,PhD, Principal investigator, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05671471
- Sponsor's protocol ID
- 2021/0099
- Other IDs
- 2021-A00746-35
- Acronym
- ALLERGY
- Status last verified
- Dec 2025
- First submitted
- 3 Nov 2022
- Last updated
- 26 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Accidental Reactions in a French Cohort of Children With Peanut and/or Tree Nut Allergy.
- ClinicalTrials.gov ID
- NCT05671471
- Acronym / sponsor ID
- ALLERGY / 2021/0099
- Conditions
- Peanut and Tree Nut Allergy
- Keywords
- Peanut allergy, tree nut allergy, peanut immunotherapy, anaphylaxis, real life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 147 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- 22 Sep 2021 (actual)
- Primary completion
- 10 Oct 2022 (actual)
- Study completion
- 10 Oct 2022 (actual)
- First posted
- 4 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Food allergy is an immune reaction, triggered by food protein allergens, of varying severity, from mild local reaction to life threatening anaphylaxis and fatalities.
Peanut is a plant from the botanical family of the Fabaceae, more commonly known as legumes. The prevalence of peanut and tree nut allergy is increasing. In France (ELFE cohort), it is estimated to 0.93%. The tree nuts include mainly almond, hazelnut, pistachio, cashew nut, walnut, pecan nut and Brazil nut. Allergy's prevalence is estimated to 0.54% in children up to 5.5 years. Peanut allergy is a main cause of anaphylaxis and deaths due to food allergy.
Recurrence of food allergy is a main concern. The risk has been estimated to 10% per year for peanut.
In France, Data in real-life on the rate of recurrence of allergic reactions and anaphylaxis to peanut/tree-nut as well as risk factors, are lacking.
The objective of this study is to assess the frequency of allergic reaction to peanut and tree-nuts, to describe the reactions' characteristics and risk factors.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Allergic Children | – | –Patients followed in the Pediatric Allergy and Pulmonology Unit, CHU Lille, aged 0-18 years with peanut and/or tree nut allergy |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients followed in the Pediatric Allergy and Pulmonology Unit, CHU Lille, aged 0-18 years with peanut and/or tree nut allergy
Key inclusion criteria (1 listed)
- Confirmed allergy to peanuts and/or nuts
Key exclusion criteria (1 listed)
- Other chronic diseases, except allergic comorbidities (asthma, rhinitis, atopic dermatitis, other food allergy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the number of episode of allergic reactions in real life
Time frame: At 1 year
3 secondary outcomes
the severity of the allergic reactions according to a validated scale (FASS scale)
Time frame: At 1 year
interview for the characteristics of the allergic reactions
Time frame: At 1 year
interview to defined the risks factor associated
Time frame: At 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Dec 2025.
Related trials for Peanut and Tree Nut Allergy
Active, not recruitingPhase 2
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Peanut Allergy, Peanut Hypersensitivity
Not yet recruiting
Oral Immunotherapy for Children With Peanut Allergy
Peanut Allergic Subjects, Peanut Allergies
RecruitingObservational study
Study of Oral Food Challenge Biomarkers (SAFER)
Allergy
RecruitingPhase 2
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
Peanut Allergy
Active, not recruitingObservational study
EPAP, Interviewstudy
Food Allergy, Food Allergy Peanut
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antoine DESCHILDRE, MD,PhD principal investigator
University Hospital, Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Peanut and Tree Nut Allergy, run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the number of episode of allergic reactions in real life (time frame: At 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Dec 2025.